It is a kinase inhibitor indicated in combination with:

• Capecitabine:  For the treatment of patients with advanced or metastatic breast cancer whose tumour overexpress HER2+/neu and who have received prior therapy including trastuzumab.
• Letrozole:  For the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated.
• Trastuzumab:  For the treatment of patients with hormone receptor – negative metastatic breast cancer whose tumours overexpress HER2/neu (ErbB2) and who have progressed on prior trastuzumab therapy in combination with metastatic setting.